What is the global market size of Morquio Syndrome Treatment Market?

Global Morquio Syndrome Treatment Market size was valued at USD 87.52 million in 2021 and is poised to grow from USD 95.72 million in 2022 to USD 188.57 million by 2030, growing at a CAGR of 9.54% in the forecast period (2023-2030).

Morquio Syndrome Treatment Market Companies

Morquio Syndrome Treatment Market Competitive Landscape

Top Players in Morquio Syndrome Treatment Market

BioMarin Pharmaceuticals Inc. (US)
Genzyme Corporation (US)
Shire plc (Ireland)
JCR Pharmaceuticals Co., Ltd. (Japan)
Sanofi (France)
Sangamo Therapeutics (US)
ArmaGen, Inc. (US)
GREEN CROSS CORP (South Korea)
Concert Pharmaceuticals Inc. (US)
Alexion Pharmaceuticals Inc. (US)
Novo Nordisk A/S (Denmark)
Eli Lilly and Company (US)
Boehringer Ingelheim International GmbH (Germany)
AstraZeneca (UK)
Amgen Inc. (US)
Merck KGaA (Germany)
Actelion Pharmaceuticals Ltd. (Switzerland)
Biocon (India)
Ultragenyx Pharmaceutical Inc. (US)
Enzyvant Therapeutics Inc. (US)

Morquio Syndrome Treatment Market Recent Development

In February 2021, to provide bottom hole assembly tools and services to directional drillers and operators in the Permian basin, SMG Industries, Inc., a Texas-based oilfield service firm, partnered with Christopher Equipment and Rentals, LLC, Texas.
In May 2021, The FDA gave Sangamo Therapeutics Inc.'s gene therapy candidate (SB-913), which is in their clinical pathway, the rare pediatric condition classification. BASF SE and NRGene (Israel) established a research agreement in October 2019, with NRGene's cloud-based artificial intelligence (AI) technology being integrated into BASF soybean research initiatives.

FAQs

Global Morquio Syndrome Treatment Market size was valued at USD 155.6 million in 2023 and is poised to grow from USD 164.62 million in 2024 to USD 258.45 million by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

In addition to recent regulatory approvals, there has been an increase in R&D for the treatment of Morquio syndrome, as shown by the increased inclusion of the condition in the clinical pipelines of the leading market participants. For the Morquio syndrome, for instance, Shire is conducting a Phase 3 Study, Ultragenyx Pharmaceutical Inc. is testing a medicine (AGT 181) in a clinical trial, and ArmaGen, Inc. is also testing a treatment for the syndrome in young patients. The market for treatments for Morquio syndrome is expanding as a result of this as well as increased disease awareness. 'BioMarin Pharmaceuticals Inc. (US) ', 'Genzyme Corporation (US) ', 'Shire plc (Ireland) ', 'JCR Pharmaceuticals Co., Ltd. (Japan) ', 'Sanofi (France) ', 'Sangamo Therapeutics (US) ', 'ArmaGen, Inc. (US) ', 'GREEN CROSS CORP (South Korea) ', 'Concert Pharmaceuticals Inc. (US) ', 'Alexion Pharmaceuticals Inc. (US) ', 'Novo Nordisk A/S (Denmark) ', 'Eli Lilly and Company (US) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'AstraZeneca (UK) ', 'Amgen Inc. (US) ', 'Merck KGaA (Germany) ', 'Actelion Pharmaceuticals Ltd. (Switzerland) ', 'Biocon (India) ', 'Ultragenyx Pharmaceutical Inc. (US) ', 'Enzyvant Therapeutics Inc. (US)'

It is projected that the market for treatments for Morquio syndrome would expand at a very rapid rate due to the increase in the number of products in the early and advanced stages of R&D as well as the focus on treating rare diseases. Several medications that are now in the pipelines of various firms can be predicted to undergo regulatory approvals for the marketing, if they have positive clinical trial results, as a result of the recent approval of the elosulfase alfa (VIMIZIM) drug.

As demonstrated by the increased inclusion of the illness in the clinical pipelines of the key market participants, there has been increased activity in R&D for the treatment of Morquio syndrome in addition to the most recent regulatory approvals. Examples include a Phase 3 Study being conducted by Ultragenyx Pharmaceutical Inc. for the Morquio syndrome, a clinical trial being conducted by the Shire for children with the syndrome, and a medication (AGT 181) being tested in clinical trials by ArmaGen, Inc. This, along with the increased public knowledge of the condition, is also fueling the market for treatments for Morquio syndrome.

The Asia Pacific is also expected to dominate the market over the forecast period owing to factors such as the rising disposable income of individuals and increasing demand for passenger cars with advanced technology from the developing countries.

Morquio Syndrome Treatment Market

Report ID: SQSG35I2026

Top Morquio Syndrome Treatment Companies

Morquio Syndrome Treatment Market Competitive Landscape

Top Players in Morquio Syndrome Treatment Market

Morquio Syndrome Treatment Market Recent Development

Morquio Syndrome Treatment Market Report Snapshots

FAQs

Request Free Customization

Top Morquio Syndrome Treatment Companies

Morquio Syndrome Treatment Market Competitive Landscape

Top Players in Morquio Syndrome Treatment Market

Morquio Syndrome Treatment Market Recent Development

Morquio Syndrome Treatment Market Report Snapshots

FAQs

What is the global market size of Morquio Syndrome Treatment Market?

Who are the key vendors in the Morquio Syndrome Treatment Market?

What is the key driver of Morquio Syndrome Treatment Market?

What is the key market trend for Morquio Syndrome Treatment Market?

Which region accounted for the largest share in Morquio Syndrome Treatment Market?

Request Free Customization